EGRX News and Press, Eagle Pharmaceuticals Inc. From 11/23/20

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company’s pre-recorded presentation at the Piper Sandler 32 nd Annual Virtual Healthcare Conference is now available for viewing via the link below: ...

Eagle Pharmaceuticals, Inc. (EGRX) Q3 2020 Earnings Conference Call Nov 02, 2020, 08:30 AM ET Company Participants Lisa Wilson - IR Scott Tarriff - CEO Brian Cahill - CFO David Pernock - President and COO Conference Call Participants Randall Stanicky - RBC Capital Tim Lugo - William Blair Bra...

Eagle Pharmaceuticals ([[EGRX]] +8.0%) Q3 results:Revenue of $49.93M (+21.3% Y/Y) beats consensus by $2.95M;  reflecting increased product sales of BELRAPZO and RYANODEX, as well as the $5.0M milestone from SymBio, partially offset by lower product sales of BENDEKA.Gr...

Eagle Pharmaceuticals (EGRX): Q3 Non-GAAP EPS of $1.17 beats by $0.88; GAAP EPS of $0.51 beats by $0.49.Revenue of $49.93M (+21.3% Y/Y) beats by $2.95M.Press Release For further details see: Eagle Pharmaceuticals EPS beats by $0.88, beats on revenue

-- Q3 2020 net income was $0.52 per basic and $0.51 per diluted share and adjusted non-GAAP net income was $1.19 per basic and $1.17 per diluted share -- -- Granted Priority Review by U.S. Food and Drug Administration (“FDA”) for vasopressin; trial date set for Jan...

-- Key additions deepen scientific, analytics and commercial expertise; positions Eagle to advance product pipeline and prepare for future commercial launches in oncology and critical care businesses -- -- Promoted Brian Cahill as Eagle’s New Chief Financial Officer -- ...

Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 third quarter financial results on Monday, November 2, 2020, before the market opens. Scott Tarriff, Chief Executive Officer, and ...

Summers Value Partners is a boutique value manager that uses a focused, long-term approach to investing in areas of the market where most managers are unwilling or unable to participate. The Summers Value Fund LP declined by 1.2% net during the first nine months of 2020, outpacing the...

Eagle Pharmaceuticals (EGRX) approved a $25M accelerated share repurchase transaction with JPMorgan as part of the existing $160M share repurchase program. $25M share repurchase would represent ~5% of the basic outstanding shares.Upon completion of the ASR, Eagle will have bought back a total...

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that its Board of Directors has approved a $25 million accelerated share repurchase (“ASR”) transaction with JPMorgan Chase Bank, National Association (“...